A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in
For more information about Intercept, please contact:
Investor inquiries: email@example.com
Media inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.